NCT00087763已完成2 期
A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 135
研究概览
简要总结
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
详细描述
This will be a randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups. Patients will be stratified by clinical center and foveal thickness to be treated either Macugen or a sham injection. After 24 weeks, all patients will treated with Macugen until the end of the study at 54 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Best corrected visual acuity in the study eye between 20/40 and 20/320 and better or equal to 20/800 in the fellow eye.
- •Foveal thickness <= 300 um (measured by OCT center point thickness).
- •Subfoveal choroidal neovascularization secondary to age-related macular degeneration, with a total lesion size (including blood, scar/atrophy & neovascularization) of <= 12 disc areas, of which at least 50% must be active CNV.
排除标准
- •Previous subfoveal thermal laser therapy.
- •Any subfoveal atrophy or scarring, blood over the fovea, or fibrosis. Additionally no more than 25% of the total lesion size may be made up of scarring or atrophy.
- •Previous photodynamic therapy with Visudyne (PDT) in the study eye. Eyes with predominantly classic lesions (as classified by fluorescein angiographic appearance) may be enrolled in the trial if, in the clinical judgment of the investigator, PDT can be deferred for at least 54 weeks after the first study treatment
研究者
相似试验
已完成
2 期
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.Macular Edema Associated With Diabetes MellitusNCT00605280Pfizer317
终止
不适用
Macugen for HistoplasmosisOcular HistoplasmosisChoroidal NeovascularizationNCT00272766Barnes Retina Institute24
已完成
不适用
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.Neovascular Age-related Macular DegenerationNCT00549055Pfizer38
已完成
4 期
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein OcclusionBranch Retinal Vein OcclusionNCT00406107Palmetto Retina Center, LLC20
已完成
1 期
A Pilot Study for the Treatment of Iris Neovascularization With MacugenIris NeovascularizationDiabetic RetinopathyNCT00295828Hermann Eye Center10